CRP and atherosclerosis: JUPITER enrolled 17 802 patients who were randomly assigned to treatment with either rosuvastatin 20 mg daily or placebo and demonstrated a 44% relative reduction in major cardiovascular events with statin therapy (HR 0.56; 95% CI 0.46-0.69, P<0.00001).30 This notion of using CRP to identify candidates for specific lipid-lowering strategies is also supported by trials among patients with established ASCVD.